Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer’s Disease?

• DOI: 10.3233/jad-215046
• Publication Date: 2021-11-12T16:09:29Z
• Authors: Ebba Gløersen Müller; Trine Holt Edwin; Bjørn Heine Strand; Caroline Stokke; Mona Elisabeth Re...; Anne-Brita Knapskog
• Keywords: Male; Amyloid beta-Peptides; Aniline Compounds; Brain; Middle Aged; 3. Good health; 03 medical and health sciences; Logistic Models; 0302 clinical medicine; Alzheimer Disease; Positron-Emission Tomography; Humans; Female; Benzothiazoles; Longitudinal Studies; Radiopharmaceuticals; Research Article; Aged

Background: Patients with Alzheimer’s disease (AD) show heterogeneity in clinical progression rate, and we have limited tools to predict prognosis. Amyloid burden from 18F-Flutemetamol positron emission tomography (PET), as measured by standardized uptake value ratios (SUVR), might provide prognostic information. Objective: We investigate whether PET composite or regional SUVRs are associated trajectories of progression. Methods: This observational longitudinal study included 94 patients AD. images were semi-quantified normalization pons. Group-based trajectory modeling was applied identify groups according change the Clinical Dementia Rating Scale Sum Boxes (CDR-SB) over time. Multinomial logistic regression models assessed association group membership. Results: Three identified. In models, neither nor Conclusion: There no associations between CDR PET-derived